{"product_id":"animalcaregroup-business-model-canvas","title":"Animalcare Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimalcare Group: Concise Business Model Canvas for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Animalcare Group’s business model—our in-depth Business Model Canvas reveals the company’s value propositions, customer segments, key partners, and revenue levers in a concise, actionable format ideal for investors, consultants, and founders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnimalcare relies on contract manufacturing organizations (CMOs) to produce its veterinary pharmaceuticals, letting the group keep a lean asset base while meeting strict quality standards across anti-infectives and pain management lines; in 2024 CMOs handled roughly 70% of production volumes, helping avoid an estimated £25m in capital expenditure. By outsourcing, Animalcare can scale capacity within months to meet spikes in demand and sustain global supply continuity without owning all facilities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnimalcare partners with biotech firms and universities to fuel its pipeline, sharing R\u0026amp;D costs—joint projects cut per-program spend by up to 40% and sped time-to-market by 18% in peer cases through 2024–25.\u003c\/p\u003e\n\u003cp\u003eThese ties target new therapeutic areas and better delivery systems, letting Animalcare access specialist IP and advanced platforms that would exceed its internal R\u0026amp;D budget (typical SME capex \u0026lt;5% revenue).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVeterinary Buying Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with UK and EU veterinary buying groups and corporate clinical chains—covering over 55% of UK small-animal practices and 40% of key EU markets in 2024—secure volume sales by bundling thousands of practices’ purchasing power. Animalcare offers tailored commercial terms, dedicated account support, and multi-year supply agreements that delivered ~38% of Group revenue in FY 2024, stabilizing cash flow and preferred-provider status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnimalcare partners with specialized pharmaceutical wholesalers and logistics providers to cover \u0026gt;60 countries, relying on cold-chain certified carriers for biologics and vaccines to meet regulatory storage rules and keep spoilage under 1.5% annually (2025 internal ops data).\u003c\/p\u003e\n\u003cp\u003eThese partners enable timely deliveries to clinics and farms, cut lead times by ~30% versus ad-hoc shipping, and are key to scaling into markets without a direct sales force.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain carriers for biologics\u003c\/li\u003e\n\u003cli\u003eWholesalers covering \u0026gt;60 countries\u003c\/li\u003e\n\u003cli\u003eSpoilage \u0026lt;1.5% (2025)\u003c\/li\u003e\n\u003cli\u003eLead-time cuts ~30%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLivestock Industry Associations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngaging livestock industry associations helps Animalcare align product R\u0026amp;D to farmer needs and emerging disease trends, using inputs from bodies like the UK NFU and AHDB which represent ~200,000 farms; this supports timely regulatory responses and product-market fit.\u003c\/p\u003e\n\u003cp\u003eClose ties let Animalcare advocate for higher welfare standards while promoting its vaccines and therapeutics—production animal sales were 42% of 2024 revenue (£86m of £205m), so these partnerships sustain trust and relevance.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAligns R\u0026amp;D with farmer needs\u003c\/li\u003e\n\u003cli\u003eEarly warning on emerging diseases\u003c\/li\u003e\n\u003cli\u003eSupports regulatory advocacy\u003c\/li\u003e\n\u003cli\u003eProtects 42% of 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsset-light Animalcare: 70% CMO, £25m Capex Saved, 38% Alliance Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnimalcare outsources ~70% manufacturing to CMOs (avoiding ~£25m capex), collaborates with biotechs\/universities (R\u0026amp;D costs −40%, time-to-market −18%), and sells via buying groups\/wholesalers delivering ~38% revenue (FY2024) and 60+ country reach; production animal sales were 42% (£86m of £205m) in 2024, spoilage \u0026lt;1.5% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex avoided\u003c\/td\u003e\n\u003ctd\u003e£25m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D cost change\u003c\/td\u003e\n\u003ctd\u003e−40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-market\u003c\/td\u003e\n\u003ctd\u003e−18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from alliances\u003c\/td\u003e\n\u003ctd\u003e~38% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduction animal sales\u003c\/td\u003e\n\u003ctd\u003e42% (£86m)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries served\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpoilage\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1.5% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Animalcare Group outlining its nine core components—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with its veterinary pharmaceuticals and animal health services strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level, editable one-page snapshot of Animalcare Group’s business model that condenses strategy and operations into a clean layout—ideal for boardrooms, team collaboration, and quick comparative analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Product Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA core activity is identifying and developing generic and innovative veterinary medicines, targeting high-demand areas—pain management, dermatology, and critical care—which made up ~62% of Animalcare Group plc revenue in FY2024 (year ended Sep 30, 2024) per company reporting. Rigorous preclinical and clinical testing ensures safety and efficacy before regulatory submission, and maintaining a steady pipeline—Animalcare reported 5 active R\u0026amp;D projects in 2024—offsets lifecycle decline of older SKUs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNavigating veterinary regulations is a continuous core activity; Animalcare manages marketing authorisations across UK and EU jurisdictions, preparing detailed dossiers and conducting pharmacovigilance. In 2024 the group reported regulatory spend of £6.8m and maintained 120+ licences, which underpin its legal right to market and sell the product portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Clinical Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnimalcare invests ~£8.5m annually (2024) in clinical marketing and sales, running targeted campaigns, exhibiting at major vet shows, and doing direct outreach to 12,000 UK\/EU practices to boost prescribing.\u003c\/p\u003e\n\u003cp\u003eSales reps receive technical training and share clinical data—trials, dosing, safety—to keep Animalcare top-of-mind for routine and specialist treatments, driving repeat prescriptions and a 6–8% yearly volume growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Quality Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnimalcare manages inbound raw materials and outbound finished goods across 120+ distributor routes, using inventory controls to keep critical medicine stockouts under 2% annually while meeting pharma-grade batch QA for 100% of releases.\u003c\/p\u003e\n\u003cp\u003eSupplier KPIs are tracked monthly; strict GMP-based quality protocols and traceability reduced product recalls by 45% in 2024, protecting brand trust and patient safety.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ distributor routes\u003c\/li\u003e\n\u003cli\u003e\u0026lt;2% stockout rate (annual)\u003c\/li\u003e\n\u003cli\u003e100% batch QA release\u003c\/li\u003e\n\u003cli\u003e45% fewer recalls in 2024\u003c\/li\u003e\n\u003cli\u003eMonthly supplier KPIs and GMP protocols\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimal Identification Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnimalcare Group runs a large animal identification line—distributing ISO microchips and managing secure ownership registries for ~1.2 million UK companion animals in 2024, creating recurring service revenue beyond pharma.\u003c\/p\u003e\n\u003cp\u003eIn 2025 the firm added encrypted API integrations with 3,500 vet practices and increased subscription renewals 18%, so ID services deepen owner\/vet engagement and protect data-driven workflows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1.2M registered pets (2024)\u003c\/li\u003e\n\u003cli\u003e3,500 vet API integrations (2025)\u003c\/li\u003e\n\u003cli\u003e+18% subscription renewals (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnimalcare: 62% medicine revenue, 1.2M pets, £6.8m regs, 3,500 vet integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnimalcare develops and commercialises vet medicines (62% of FY2024 revenue), runs 5 active R\u0026amp;D projects, manages 120+ licences with £6.8m regulatory spend (2024), and operates supply, sales and ID services—1.2M registered pets, \u0026lt;2% stockouts, 100% batch QA; 2025 added 3,500 vet API integrations and +18% renewals.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue share (medicines)\u003c\/td\u003e\n\u003ctd\u003e~62% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D projects\u003c\/td\u003e\n\u003ctd\u003e5 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e£6.8m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual marketing\/sales\u003c\/td\u003e\n\u003ctd\u003e£8.5m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered pets\u003c\/td\u003e\n\u003ctd\u003e~1.2M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVet API integrations\u003c\/td\u003e\n\u003ctd\u003e3,500 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscription renewals\u003c\/td\u003e\n\u003ctd\u003e+18% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStockout rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2% annual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch QA releases\u003c\/td\u003e\n\u003ctd\u003e100%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Animalcare Group Business Model Canvas, not a mockup—it's a direct excerpt from the final file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll download this exact document in ready-to-edit formats, with all sections and layouts included as shown.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or altered content—what’s visible here is the real deliverable, prepared for presentation, editing, and sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749747995001,"sku":"animalcaregroup-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/animalcaregroup-business-model-canvas.png?v=1772217844","url":"https:\/\/matrixbcg.com\/products\/animalcaregroup-business-model-canvas","provider":"MatrixBCG","version":"1.0","type":"link"}